Top

Published in:

01-10-2018 | Original Article

Baicalin Attenuates Blood-Brain Barrier Disruption and Hemorrhagic Transformation and Improves Neurological Outcome in Ischemic Stroke Rats with Delayed t-PA Treatment: Involvement of ONOO⁻-MMP-9 Pathway

Authors: Hansen Chen, Binghe Guan, Xi Chen, Xingmiao Chen, Caiming Li, Jinhua Qiu, Dan Yang, Ke Jian Liu, Suhua Qi, Jiangang Shen

Published in: Translational Stroke Research | Issue 5/2018

Abstract

Tissue plasminogen activator (t-PA) has a restrictive therapeutic window within 4.5 h after ischemic stroke with the risk of hemorrhagic transformation (HT) and neurotoxicity when it is used beyond the time window. In the present study, we tested the hypothesis that baicalin, an active compound of medicinal plant, could attenuate HT in cerebral ischemia stroke with delayed t-PA treatment. Male Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) for 4.5 h and then continuously received t-PA infusion (10 mg/kg) for 0.5 h and followed by 19-h reperfusion. Baicalin (50, 100, 150 mg/kg) was administrated via femoral vein at 4.5 h after MCAO cerebral ischemia. Delayed t-PA infusion significantly increased the mortality rate, induced HT, blood-brain barrier (BBB) damage, and apoptotic cell death in the ischemic brains and exacerbated neurological outcomes in cerebral ischemia-reperfusion rats at 24 h after MCAO cerebral ischemia. Co-treatment of baicalin significantly reduced the mortality rates, ameliorated the t-PA-mediated BBB disruption and HT. Furthermore, baicalin showed to directly scavenge peroxynitrite and inhibit MMP-9 expression and activity in the ischemic brains with the delayed t-PA treatment. Baicalin had no effect on the t-PA fibrinolytic function indicated by t-PA activity assay. Taken together, baicalin could attenuate t-PA-mediated HT and improve the outcomes of ischemic stroke treatment possibly via inhibiting peroxynitrite-mediated MMP-9 activation.

Available only for authorised users

Heron M, Statistics V. Leading causes for 2007. National vital statistics reports Hyattsville, MD: National Center for Health Statistics 2011.

Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics—2011 update. Circulation. 2011;123(4):e18–e209. https://doi.org/10.1161/CIR.0b013e3182009701.CrossRefPubMed

Cheng NT, Kim AS. Intravenous thrombolysis for acute ischemic stroke within 3 hours versus between 3 and 4.5 hours of symptom onset. Neurohospitalist. 2015;5(3):101–9. https://doi.org/10.1177/1941874415583116.CrossRefPubMedPubMedCentral

Kanazawa M, Takahashi T, Nishizawa M, Shimohata T. Therapeutic strategies to attenuate hemorrhagic transformation after tissue plasminogen activator treatment for acute ischemic stroke. J Atheroscler Thromb. 2017;24(3):240–53. https://doi.org/10.5551/jat.RV16006.CrossRefPubMedPubMedCentral

Lees KR, Bluhmki E, Von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–703. https://doi.org/10.1016/S0140-6736(10)60491-6.CrossRefPubMed

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133(4):447–54. https://doi.org/10.1161/CIR.0000000000000366.CrossRefPubMed

Bang OY, Buck BH, Saver JL, Alger JR, Yoon SR, Starkman S, et al. Prediction of hemorrhagic transformation after recanalization therapy using T2*-permeability magnetic resonance imaging. Ann Neurol. 2007;62(2):170–6. https://doi.org/10.1002/ana.21174.CrossRefPubMed

Hamann GF, del Zoppo GJ, von Kummer R. Hemorrhagic transformation of cerebral infarction–possible mechanisms. Thromb Haemost. 1999;82(1):92–4.PubMed

Hemorrhagic PEPF. MRI Detection of early blood-brain barrier disruption. Brain. 2008;39:1025–8.

10.

Chen H, Guan B, Shen J. Targeting ONOO-/HMGB1/MMP-9 signaling cascades: potential for drug development from Chinese Medicine to attenuate ischemic brain injury and hemorrhagic transformation induced by thrombolytic treatment. Integr Med Int. 2016;3(1–2):32–52. https://doi.org/10.1159/000442468.CrossRef

11.

Chen HS, Qi SH, Shen JG. One-compound-multi-target: combination prospect of natural compounds with thrombolytic therapy in acute ischemic stroke. Curr Neuropharmacol. 2017;15(1):134–56.CrossRefPubMedPubMedCentral

12.

Jickling GC, Liu D, Stamova B, Ander BP, Zhan X, Lu A, et al. Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab. 2014;34(2):185–99. https://doi.org/10.1038/jcbfm.2013.203.CrossRefPubMed

13.

Liu KJ, Rosenberg GA. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med. 2005;39(1):71–80.CrossRef

14.

Pun PB, Lu J, Moochhala S. Involvement of ROS in BBB dysfunction. Free Radic Res. 2009;43(4):348–64. https://doi.org/10.1080/10715760902751902.CrossRefPubMed

15.

Yamashita T, Abe K. Therapeutic approaches to vascular protection in ischemic stroke. Acta Med Okayama. 2011;65(4):219–23. https://doi.org/10.18926/AMO/46846.PubMedCrossRef

16.

Gu Y, Dee CM, Shen J. Interaction of free radicals, matrix metalloproteinases and caveolin-1 impacts blood-brain barrier permeability. Front Biosci (Schol Ed). 2011;3(3):1216–31.CrossRef

17.

Shen J, Ma S, Chan P, Lee W, Fung PC, Cheung RT, et al. Nitric oxide down-regulates caveolin-1 expression in rat brains during focal cerebral ischemia and reperfusion injury. J Neurochem. 2006;96(4):1078–89. https://doi.org/10.1111/j.1471-4159.2005.03589.x.CrossRefPubMed

18.

Gu Y, Zheng G, Xu M, Li Y, Chen X, Zhu W, et al. Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity and blood–brain barrier permeability in focal cerebral ischemia and reperfusion injury. J Neurochem. 2012;120(1):147–56. https://doi.org/10.1111/j.1471-4159.2011.07542.x.CrossRefPubMed

19.

Lakhan SE, Kirchgessner A, Tepper D, Leonard A. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol. 2013;4:32. https://doi.org/10.3389/fneur.2013.00032.PubMedPubMedCentralCrossRef

20.

Groves JT. Peroxynitrite: reactive, invasive and enigmatic. Curr Opin Chem Biol. 1999;3(2):226–35. https://doi.org/10.1016/S1367-5931(99)80036-2.CrossRefPubMed

21.

Kuhn DM, Sakowski SA, Sadidi M, Geddes TJ. Nitrotyrosine as a marker for peroxynitrite-induced neurotoxicity: the beginning or the end of the end of dopamine neurons? J Neurochem. 2004;89(3):529–36. https://doi.org/10.1111/j.1471-4159.2004.02346.x.CrossRefPubMed

22.

Takizawa S, Fukuyama N, Hirabayashi H, Nakazawa H, Shinohara Y. Dynamics of nitrotyrosine formation and decay in rat brain during focal ischemia-reperfusion. J Cereb Blood Flow Metab. 1999;19(6):667–72. https://doi.org/10.1097/00004647-199906000-00010.CrossRefPubMed

23.

Takizawa S, Hirabayashi H, Fukuyama N, Nakazawa H, Shinohara Y. Peroxynitrite production in cerebral ischemia. Rinsho Shinkeigaku. 1999;39(12):1295–7.PubMed

24.

Suzuki M, Tabuchi M, Ikeda M, Tomita T. Concurrent formation of peroxynitrite with the expression of inducible nitric oxide synthase in the brain during middle cerebral artery occlusion and reperfusion in rats. Brain Res. 2002;951(1):113–20. https://doi.org/10.1016/S0006-8993(02)03145-1.CrossRefPubMed

25.

Chen HS, Chen XM, Feng JH, Liu KJ, Qi SH, Shen JG. Peroxynitrite decomposition catalyst reduces delayed thrombolysis-induced hemorrhagic transformation in ischemia-reperfused rat brains. CNS Neurosci Ther. 2015;21(7):585–90. https://doi.org/10.1111/cns.12406.CrossRefPubMed

26.

Romanos E, Planas AM, Amaro S, Chamorro Á. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab. 2007;27(1):14–20. https://doi.org/10.1038/sj.jcbfm.9600312.CrossRefPubMed

27.

Amaro S, Urra X, Gomez-Choco M, Obach V, Cervera A, Vargas M, et al. Uric acid levels are relevant in patients with stroke treated with thrombolysis. Stroke. 2011;42(1 Suppl):S28–32. https://doi.org/10.1161/STROKEAHA.110.596528.CrossRefPubMed

28.

Lee S-H, Heo SH, Kim J-H, Lee D, Lee JS, Kim YS, et al. Effects of uric acid levels on outcome in severe ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator. Eur Neurol. 2014;71(3–4):132–9. https://doi.org/10.1159/000355020.CrossRefPubMed

29.

Liu X, Liu M, Chen M, Ge Q-M, Pan S-M. Serum uric acid is neuroprotective in Chinese patients with acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator. J Stroke Cerebrovasc Dis. 2015;24(5):1080–6. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.01.011.CrossRefPubMed

30.

Chuanyun L, Yanshu P, Xu J. Effects of Huangqin (dried root of Scutellaria baicalensis) and Zhizi (dried fruit of Gardenia jasminoides) used in combination on ischemic cascade reaction in the rat model of focal cerebral ischemia and reperfusion. J Beijing Univ Tradit Chin Med. 2002;25(6):31–3.

31.

Singh DP, Chopra K. Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke. Pharmacol Biochem Behav. 2014;120:33–42. https://doi.org/10.1016/j.pbb.2014.02.006.CrossRefPubMed

32.

Tu X-K, Yang W-Z, Liang R-S, Shi S-S, Chen J-P, Chen C-M, et al. Effect of baicalin on matrix metalloproteinase-9 expression and blood–brain barrier permeability following focal cerebral ischemia in rats. Neurochem Res. 2011;36(11):2022.CrossRefPubMed

33.

Zhu H, Wang Z, Xing Y, Gao Y, Ma T, Lou L, et al. Baicalin reduces the permeability of the blood–brain barrier during hypoxia in vitro by increasing the expression of tight junction proteins in brain microvascular endothelial cells. J Ethnopharmacol. 2012;141(2):714–20. https://doi.org/10.1016/j.jep.2011.08.063.CrossRefPubMed

34.

Xu M, Chen X, Gu Y, Peng T, Yang D, Chang RC-C, et al. Baicalin can scavenge peroxynitrite and ameliorate endogenous peroxynitrite-mediated neurotoxicity in cerebral ischemia-reperfusion injury. J Ethnopharmacol. 2013;150(1):116–24. https://doi.org/10.1016/j.jep.2013.08.020.CrossRefPubMed

35.

Liu W, Hendren J, Qin X-J, Liu KJ. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke. 2009;40(7):2526–31. https://doi.org/10.1161/STROKEAHA.108.545483.CrossRefPubMedPubMedCentral

36.

Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981;46(2):561–5.CrossRefPubMed

37.

Xue X, Qu X-J, Yang Y, Sheng X-H, Cheng F, Jiang E-N, et al. Baicalin attenuates focal cerebral ischemic reperfusion injury through inhibition of nuclear factor κB p65 activation. Biochem Biophys Res Commun. 2010;403(3):398–404. https://doi.org/10.1016/j.bbrc.2010.11.042.CrossRefPubMed

38.

Qiu J, Niu X, Dong J, Wang D, Wang J, Li H, et al. Baicalin protects mice from Staphylococcus aureus pneumonia via inhibition of the cytolytic activity of α-hemolysin. J Infect Dis. 2012;206(2):292–301. https://doi.org/10.1093/infdis/jis336.CrossRefPubMed

39.

Thiyagarajan M, Kaul CL, Sharma SS. Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats. Br J Pharmacol. 2004;142(5):899–911. https://doi.org/10.1038/sj.bjp.0705811.CrossRefPubMedPubMedCentral

40.

Fagan SC, Lapchak PA, Liebeskind DS, Ishrat T, Ergul A. Recommendations for preclinical research in hemorrhagic transformation. Transl Stroke Res. 2013;4(3):322–7. https://doi.org/10.1007/s12975-012-0222-5.CrossRefPubMed

41.

Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke. 2001;32(11):2682–8. https://doi.org/10.1161/hs1101.098367.CrossRefPubMed

42.

Naderi V, Khaksari M, Abbasi R, Maghool F. Estrogen provides neuroprotection against brain edema and blood brain barrier disruption through both estrogen receptors α and β following traumatic brain injury. Iran J Basic Med Sci. 2015;18(2):138–44.PubMedPubMedCentral

43.

Liu W, Sood R, Chen Q, Sakoglu U, Hendren J, Çetin Ö, et al. Normobaric hyperoxia inhibits NADPH oxidase-mediated matrix metalloproteinase-9 induction in cerebral microvessels in experimental stroke. J Neurochem. 2008;107(5):1196–205. https://doi.org/10.1111/j.1471-4159.2008.05664.x.CrossRefPubMedPubMedCentral

44.

García-Yébenes I, Sobrado M, Zarruk JG, Castellanos M, de la Ossa NP, Dávalos A, et al. A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke. Stroke. 2011;42(1):196–203. https://doi.org/10.1161/STROKEAHA.110.600452.CrossRefPubMed

45.

Gao L, Chen X, Peng T, Yang D, Wang Q, Lv Z, et al. Caveolin-1 protects against hepatic ischemia/reperfusion injury through ameliorating peroxynitrite-mediated cell death. Free Radic Biol Med. 2016;95:209–15. https://doi.org/10.1016/j.freeradbiomed.2016.03.023.CrossRefPubMed

46.

Peng T, Chen X, Gao L, Zhang T, Wang W, Shen J, et al. A rationally designed rhodamine-based fluorescent probe for molecular imaging of peroxynitrite in live cells and tissues. Chem Sci. 2016;7(8):5407–13. https://doi.org/10.1039/C6SC00012F.CrossRefPubMedPubMedCentral

47.

Watanabe T, Okuda Y, Nonoguchi N, Zhao MZ, Kajimoto Y, Furutama D, et al. Postischemic intraventricular administration of FGF-2 expressing adenoviral vectors improves neurologic outcome and reduces infarct volume after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2004;24(11):1205–13. https://doi.org/10.1097/01.WCB.0000136525.75839.41.CrossRefPubMed

48.

Ding R, Feng L, He L, Chen Y, Wen P, Fu Z, et al. Peroxynitrite decomposition catalyst prevents matrix metalloproteinase-9 activation and neurovascular injury after hemoglobin injection into the caudate nucleus of rats. Neuroscience. 2015;297:182–93. https://doi.org/10.1016/j.neuroscience.2015.03.065.CrossRefPubMed

49.

Suofu Y, Clark J, Broderick J, Wagner KR, Tomsick T, Sa Y, et al. Peroxynitrite decomposition catalyst prevents matrix metalloproteinase activation and neurovascular injury after prolonged cerebral ischemia in rats. J Neurochem. 2010;115(5):1266–76. https://doi.org/10.1111/j.1471-4159.2010.07026.x.CrossRefPubMedPubMedCentral

50.

Wang P, Cao Y, Yu J, Liu R, Bai B, Qi H, et al. Baicalin alleviates ischemia-induced memory impairment by inhibiting the phosphorylation of CaMKII in hippocampus. Brain Res. 2016;1642:95–103. https://doi.org/10.1016/j.brainres.2016.03.019.CrossRefPubMed

51.

Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus. 2007;22(5):1–9. https://doi.org/10.3171/foc.2007.22.5.5.CrossRef

52.

Yang Y, Rosenberg GA. MMP-mediated disruption of claudin-5 in the blood–brain barrier of rat brain after cerebral ischemia. Methods Mol Biol. 2011;762:333–45. https://doi.org/10.1007/978-1-61779-185-7_24.

53.

Castellanos M, Sobrino T, Millán M, García M, Arenillas J, Nombela F, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke. Stroke. 2007;38(6):1855–9. https://doi.org/10.1161/STROKEAHA.106.481556.CrossRefPubMed

54.

Tang G, Yang G-Y. Aquaporin-4: a potential therapeutic target for cerebral edema. Int J Mol Sci. 2016;17(10):1413. https://doi.org/10.3390/ijms17101413.CrossRefPubMedCentral

55.

Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87(1):315–424. https://doi.org/10.1152/physrev.00029.2006.CrossRefPubMedPubMedCentral

56.

Virág L, Szabo E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett. 2003;140:113–24.CrossRefPubMed

57.

Zheng W-X, Cao X-L, Wang F, Wang J, Ying T-Z, Xiao W, et al. Baicalin inhibiting cerebral ischemia/hypoxia-induced neuronal apoptosis via MRTF-A-mediated transactivity. Eur J Pharmacol. 2015;767:201–10. https://doi.org/10.1016/j.ejphar.2015.10.027.CrossRefPubMed

58.

Zheng W-X, Wang F, Cao X-L, Pan H-Y, Liu X-Y, Hu X-M, et al. Baicalin protects PC-12 cells from oxidative stress induced by hydrogen peroxide via anti-apoptotic effects. Brain Inj. 2014;28(2):227–34. https://doi.org/10.3109/02699052.2013.860469.CrossRefPubMed

59.

Hou J, Wang J, Zhang P, Li D, Zhang C, Zhao H, et al. Baicalin attenuates proinflammatory cytokine production in oxygen–glucose deprived challenged rat microglial cells by inhibiting TLR4 signaling pathway. Int Immunopharmacol. 2012;14(4):749–57. https://doi.org/10.1016/j.intimp.2012.10.013.CrossRefPubMed

60.

Shi X, Fu Y, Zhang S, Ding H, Chen J. Baicalin attenuates subarachnoid hemorrhagic brain injury by modulating blood-brain barrier disruption, inflammation, and oxidative damage in mice. Oxidative Med Cell Longev. 2017;2017:1–9. https://doi.org/10.1155/2017/1401790.CrossRef

61.

Tu X-K, Yang W-Z, Shi S-S, Chen Y, Wang C-H, Chen C-M, et al. Baicalin inhibits TLR2/4 signaling pathway in rat brain following permanent cerebral ischemia. Inflammation. 2011;34(5):463–70.CrossRefPubMed

62.

Bai Y, Xu G, Xu M, Li Q, Qin X. Inhibition of Src phosphorylation reduces damage to the blood-brain barrier following transient focal cerebral ischemia in rats. Int J Mol Med. 2014;34(6):1473–82. https://doi.org/10.3892/ijmm.2014.1946.CrossRefPubMedPubMedCentral

63.

Cui L, Zhang X, Yang R, Liu L, Wang L, Li M, et al. Baicalein is neuroprotective in rat MCAO model: role of 12/15-lipoxygenase, mitogen-activated protein kinase and cytosolic phospholipase A2. Pharmacol Biochem Behav. 2010;96(4):469–75. https://doi.org/10.1016/j.pbb.2010.07.007.CrossRefPubMed

64.

Yigitkanli K, Zheng Y, Pekcec A, Lo EH, van Leyen K. Increased 12/15-lipoxygenase leads to widespread brain injury following global cerebral ischemia. Transl Stroke Res. 2017;8(2):194–202. https://doi.org/10.1007/s12975-016-0509-z.CrossRefPubMed

65.

van Leyen K, Kim HY, Lee S-R, Jin G, Arai K, Lo EH. Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke. 2006;37(12):3014–8. https://doi.org/10.1161/01.STR.0000249004.25444.a5.CrossRefPubMed

66.

Jin G, Arai K, Murata Y, Wang S, Stins MF, Lo EH, et al. Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia. Stroke. 2008;39(9):2538–43. https://doi.org/10.1161/STROKEAHA.108.514927.CrossRefPubMedPubMedCentral

67.

Lee JH, Lee SR. The effect of baicalein on hippocampal neuronal damage and metalloproteinase activity following transient global cerebral ischaemia. Phytother Res. 2012;26(11):1614–9. https://doi.org/10.1002/ptr.4644.CrossRefPubMed

68.

Liu Y, Zheng Y, Karatas H, Wang X, Foerch C, Lo EH, et al. 12/15-Lipoxygenase inhibition or knockout reduces warfarin-associated hemorrhagic transformation after experimental stroke. Stroke. 2017;48(2):445–51. https://doi.org/10.1161/STROKEAHA.116.014790.CrossRefPubMedPubMedCentral

69.

Karatas H, Jung JE, Lo E, van Leyen K. Inhibiting 12/15-lipoxygenase to treat acute stroke in permanent and tPA induced thrombolysis models. Brain Res. 1678;2018:123–8.

70.

Zhang Y, Wang H, Li J, Jimenez DA, Levitan ES, Aizenman E, et al. Peroxynitrite-induced neuronal apoptosis is mediated by intracellular zinc release and 12-lipoxygenase activation. J Neurosci. 2004;24(47):10616–27. https://doi.org/10.1523/JNEUROSCI.2469-04.2004.CrossRefPubMedPubMedCentral

71.

Huang H, Zhang Y, Yang R, Tang X. Determination of baicalin in rat cerebrospinal fluid and blood using microdialysis coupled with ultra-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2008;874(1):77–83. https://doi.org/10.1016/j.jchromb.2008.09.005.CrossRef

72.

Zeng M-F, Pan L-M, Zhu H-X, Zhang Q-C, Guo L-W. Comparative pharmacokinetics of baicalin in plasma after oral administration of Huang-Lian-Jie-Du-Tang or pure baicalin in MCAO and sham-operated rats. Fitoterapia. 2010;81(6):490–6. https://doi.org/10.1016/j.fitote.2010.01.004.CrossRefPubMed

73.

Tu X-K, Yang W-Z, Shi S-S, Wang C-H, Chen C-M. Neuroprotective effect of baicalin in a rat model of permanent focal cerebral ischemia. Neurochem Res. 2009;34(9):1626–34.CrossRefPubMed

74.

Zhou Q-B, Jin Y-L, Jia Q, Zhang Y, Li L-Y, Liu P, et al. Baicalin attenuates brain edema in a rat model of intracerebral hemorrhage. Inflammation. 2014;37(1):107–15. https://doi.org/10.1007/s10753-013-9717-9.CrossRefPubMed

Title: Baicalin Attenuates Blood-Brain Barrier Disruption and Hemorrhagic Transformation and Improves Neurological Outcome in Ischemic Stroke Rats with Delayed t-PA Treatment: Involvement of ONOO−-MMP-9 Pathway
Authors: Hansen Chen
Binghe Guan
Xi Chen
Xingmiao Chen
Caiming Li
Jinhua Qiu
Dan Yang
Ke Jian Liu
Suhua Qi
Jiangang Shen
Publication date: 01-10-2018
Publisher: Springer US
Published in: Translational Stroke Research / Issue 5/2018
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-017-0598-3

At a glance: The STEP trials

Springer Medicine

Baicalin Attenuates Blood-Brain Barrier Disruption and Hemorrhagic Transformation and Improves Neurological Outcome in Ischemic Stroke Rats with Delayed t-PA Treatment: Involvement of ONOO⁻-MMP-9 Pathway

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

Effect of TTC Treatment on Immunohistochemical Quantification of Collagen IV in Rat Brains after Stroke

Association Between Splenic Contraction and the Systemic Inflammatory Response After Acute Ischemic Stroke Varies with Age and Race

Inhibition of VEGF Signaling Reduces Diabetes-Exacerbated Brain Swelling, but Not Infarct Size, in Large Cerebral Infarction in Mice

Ras-Related C3 Botulinum Toxin Substrate 1 Promotes Axonal Regeneration after Stroke in Mice

Influence of Thrombolysis on the Safety and Efficacy of Blocking Platelet Adhesion or Secretory Activity in Acute Ischemic Stroke in Mice

Photothrombotic Stroke as a Model of Ischemic Stroke